SCHEMBL24569044

SCHEMBL24569044

Fc1ccc(Cl)cc1-c1cc(Cl)c2c(n1)NCCO2

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.38
TGFBR1 P36897 4/20 0.37
RET P07949 4/20 0.35
FABP6 P51161 1/20 0.35
CNR1 P21554 1/20 0.35
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
KMO O15229 1/20 0.32
F7 P08709 1/20 0.32
PARP1 P09874 1/20 0.32
F3 P13726 1/20 0.32
PARP10 Q53GL7 1/20 0.32
LRRK2 Q5S007 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
PTGES O14684 1/20 0.31
APEX1 P27695 1/20 0.31
AKT1S1 Q96B36 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29694459 1.00 EGFR (0.38) EGFRTGFBR1RETFABP6CNR1
SCHEMBL24568262 0.88 TGFBR1 (0.35) EGFRTGFBR1RETFABP6CNR1
SCHEMBL29694456 0.88 TGFBR1 (0.35) EGFRTGFBR1RETFABP6CNR1
SCHEMBL24568273 0.88 TGFBR1 (0.35) EGFRTGFBR1RETFABP6CNR1
SCHEMBL30366222 0.85 TGFBR1 (0.41) EGFRTGFBR1RETFABP6CNR1
SCHEMBL27200470 0.85 TGFBR1 (0.41) EGFRTGFBR1RETFABP6CNR1
SCHEMBL29694433 0.83 MEN1 (0.36) EGFRTGFBR1RETFABP6CNR1
SCHEMBL24568840 0.82 BCHE (0.41) CYP1A2CYP3A4
SCHEMBL29694328 0.82 CYP3A4 (0.36) EGFRTGFBR1RETCNR1CYP1A2
SCHEMBL24568389 0.82 CYP3A4 (0.36) EGFRTGFBR1RETCNR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116948-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-04-11 US disclosed
EP-4267584-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-11-01 EP disclosed
WO-2022136221-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-30 WO disclosed
WO-2022136221-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116948-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS TGFBR1, ACVR1, TGFBR2 EGFR 84/4885TGFBR1 1/4885RET 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.